Drug Approval | October 23, 2023
Zhimeng Biopharma CB03 receives Orphan Drug Designation from the USFDA
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The composition of ORAAL is protected by a granted patent in India until November 2033
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
Subscribe To Our Newsletter & Stay Updated
